Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 5/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.42 |
| ▸ | MERTK | Q12866 | 5/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 5/20 | 0.42 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876567 | 0.77 | LRRK2 (0.39) | FLT3TYRO3MERTKAXL | |
| Hydrochloric Acid SCHEMBL1521798 | 0.76 | LRRK2 (0.38) | FLT3TYRO3MERTKAXL | |
| SCHEMBL12876603 | 0.76 | L3MBTL1 (0.70) | L3MBTL1 | |
| SCHEMBL5411447 | 0.76 | STK17A (0.66) | — | |
| SCHEMBL4194117 | 0.75 | TLR8 (0.44) | L3MBTL1TLR8TLR7 | |
| SCHEMBL10996367 | 0.73 | TLR8 (0.43) | L3MBTL1TLR8SLC29A1FLT3TYRO3 | |
| SCHEMBL29290149 | 0.72 | STK17A (0.44) | — | |
| SCHEMBL15584702 | 0.71 | ALDH1A1 (0.36) | L3MBTL1FLT3TYRO3MERTKGAS6 | |
| SCHEMBL17209853 | 0.71 | STK17A (0.47) | — | |
| SCHEMBL27901222 | 0.71 | KDM4E (0.42) | TLR7FLT3TYRO3MERTKGAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046131-A1 | PURINES AS PKC-THETA INHIBITORS | N.V. Organon and Pharmacopeia, LLC | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046131-A1 | PURINES AS PKC-THETA INHIBITORS | PRKCQ, PRKCE, PRKCH | L3MBTL1 3625/4885TLR8 3728/4885TLR7 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.